Cargando…

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply

Detalles Bibliográficos
Autores principales:	Cavalli, Giulio, Larcher, Alessandro, Tomelleri, Alessandro, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990474/ https://www.ncbi.nlm.nih.gov/pubmed/33782670 http://dx.doi.org/10.1016/S2665-9913(21)00066-7

Ejemplares similares

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation
por: Marwah, Vikas, et al.
Publicado: (2021)

Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle
por: Farina, Nicola, et al.
Publicado: (2022)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

Assessing the importance of interleukin-6 in COVID-19
por: Chen, Luke Y C, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
por: Bovijn, Jonas, et al.
Publicado: (2021)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
por: Vlaar, Alexander P J, et al.
Publicado: (2021)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Authors’ reply to Hansel’s letter to the editor
por: Kotani, Yuki, et al.
Publicado: (2023)

Authors' Reply
por: Herrera, Daniel, et al.
Publicado: (2006)

The right place for IL-1 inhibition in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

COVID-19 and preterm birth – Authors' reply
por: Choudhary, Rahul, et al.
Publicado: (2021)

Neuropsychiatric disorders and COVID-19 – Authors' reply
por: Taquet, Maxime, et al.
Publicado: (2021)

COVID-19 and myocardial infarction – Authors' reply
por: Katsoularis, Ioannis, et al.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

COVID-19 research in LMICs – Authors' reply
por: Torres, Irene, et al.
Publicado: (2021)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Authors’ reply to the comment from Glass et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Frailty and mortality in patients with COVID-19 – Authors' reply
por: McCarthy, Kathryn, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Psychiatric and neuropsychiatric syndromes and COVID-19 – Authors' reply
por: Rogers, Jonathan P, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ghpr8mtsuqorv100ft1959m17r